Abstract 155P
Background
Circulating tumor cells (CTCs) are cells of epithelial origin from clones of the primary tumor, located in the G0 phase and found in the peripheral blood of patients with various forms of solid cancer. Currently, CTCs are found in breast cancer, prostate cancer, colorectal cancer, and their number is used as an independent prognostic factor. The detection of CTCs in various tumors can help in the study of the process of metastasis and the biology of tumor growth. The aim of the work is to establish the presence and frequency of CTCs in the peripheral blood of patients with cancer in the bladder.
Methods
41 peripheral blood samples from patients with verified bladder cancer of stage III-IV were analyzed. The blood was taken into vacuum tubes with anticoagulant. The selection of the CTC on the density gradient. From the obtained material, 2 cytological preparations were prepared on the cytocentrifuge of Hospitex diagnostics (Italy) and stained according to Romanovsky. Calculation of the CTC at the light-optical level using a Zeiss Primo Star microscope (Germany). The final result was the total number of detected CTCs. The control group consisted of peripheral blood samples from 10 patients without cancer.
Results
CTCs were detected in 46.3% of cases (19 samples) in the amount of 1-14 cells. In the morphological structure of primary tumors, according to the results of histological examination, the samples were divided as follows: squamous cell carcinoma – 1, adenocarcinoma (metastasis of cervical cancer) – 1, urothelial carcinoma – 17. The calculation of the CTC by morphological forms of the tumor showed that 4-6 cells were detected in squamous cell carcinoma, 6 cells in adenocarcinoma, and 2 - 14 cells in urothelial carcinoma (2-4 cells in the II st., 7-14 cells in the IIII st.; Xsr=2.43). In the blood samples of the control patients, CTCs were also not detected.
Conclusions
The presence of CTC in the peripheral blood of patients with bladder cancer was detected in 46.3% of cases and has differences depending on the morphological form of the tumor, which requires further study. The largest number of CTCs in our study was revealed in the transitional cell (urothelial) morphological form of cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
140P - Lenvatinib + everolimus in mRCC that has progressed on immunotherapy: A real-world single center experience
Presenter: CHINNU JOMI
Session: Poster viewing 03
141P - Real-world study of cabozantinib treatment of advanced renal cell carcinoma in Taiwan
Presenter: Yu-Chieh Tsai
Session: Poster viewing 03
143P - Clinical outcomes of systemic therapy for hemodialysis patients with metastatic renal cell carcinoma
Presenter: Shun Iwasa
Session: Poster viewing 03
144P - Association between immune-related adverse events and survival in metastatic renal cell carcinoma treated with nivolumab plus ipilimumab
Presenter: Takanori Hayase
Session: Poster viewing 03
145P - Treatment outcomes and FGFR alterations in unresectable locally advanced or metastatic urothelial cancer in Taiwan
Presenter: Jian-Ri Li
Session: Poster viewing 03
146P - Comparison of the survival outcomes between primary and secondary muscle-invasive bladder cancer: A propensity score-matched Chinese cohort
Presenter: WAICHAN LOK
Session: Poster viewing 03
Resources:
Abstract
147P - Activity of single-agent PD-1/PD-L1 inhibitors in 1st-line (1L) “platinum-ineligible” patients (pts) with metastatic urothelial cancer (mUC) in real-life clinical practice
Presenter: Javier Molina Cerrillo
Session: Poster viewing 03
149P - A need for clear definitions and improved management for BCG-unresponsive tumors in Asia-Pacific
Presenter: Lui Shiong Lee
Session: Poster viewing 03
Resources:
Abstract